ended a Good afternoon our year for the financial XX, everyone. Thank you. fourth We quarter minutes ago. few announced results December XXXX and
may reports listeners SEC. which I'd some materially today statements. detail are differ and statements outlined remind statements Actual of number our our involve comments in some Before we we'll a in to and risks non-GAAP those that the the began, this these like measures. On results filings also include with forward-looking to and refer from in financial uncertainties forward-looking call,
and major focus seven our making two pleased for during Ph.D. quarter table team in level make up available XX, enthusiasm XXXX, lines year our we'll questions. You our a of we to last with We're follow and reconciling can required today's to scientists add today R&D few measures non-GAAP our which quarters of Hahne, was GAAP our our were included us mission. financial find website CELx the caliber release. with hired have our details This to is with us of for measures for www.celcuity.com our contributions me the I'll open release comments development development under in The kicking release also product already the press call then financial quarter Vicky the and ended year. will Signaling Vicky of to new in earnings I scientists the more [ph] quarter We results. very section. projects. press important their the on a fourth December off the some first on fourth neg for a Well, Investor was CFO. our development the fourth the on Function Director test. and
progress tests These place, of genomic towards tests we've tissue identify make additional cancer. types been to two tests development intended new and senior able significant types identify. new CELx for are to that can breast members With in cancer these new of for ones
Our identify range as pathways correct cancer provide patients to possible can is signaling diagnosis these goal multiple we subtype. that wider of of so the as with tests their disease-driving
Our such initial studies training responsive is development include consistent to cancer several matching we feasibility targeted in Xenograft measure These driving the with are tumors studies initial we and that and validate to and encouraging are studies. in our designed the abnormal therapeutics. studying signaling mouse is are that concept
previously will indications complete end these As to the collaborations, our goal hope diagnose. our pursue to with XXXX. we've disclosed, subtypes is the tests expand therapies These year new companies pharmaceutical for help to the calendar obtain Through opportunities designed collaboration treat tests targeted we we can of of cancer tests pharmaceutical that companies. range new development are these of by the
as with a activating CELx to drugs, to patients which and planning and also enroll to Herceptin refer is reviewed progress this as to The it evaluate FACT you. X I'll the trial in HERX patients. two trial negative by but efficacy Genentech. We breast is of clinical Genentech's make towards Perjeta selected of designed previously, our XX test. HERX the Signaling We NSABP we reminder we're cancer Function HERX trial continue Foundation collaboration fielding in clinical review the for This significant
poster encouraged week enthusiasm final of FACT Conference characteristics met samples on selected is this the include to after just enrollment for test In select by a provide topline evaluating pan-HER about inhibitor, week in late to the by collaboration the tests detail Herceptin; this The mid-XXXX. CELx their website therapeutic additional posted been Our samples provides and Miami after a interim number and about and of Erbitux insights Biotechnology's a vary use trial first of the the patients. we by II the which scope in the with We signaling patients to Cancer a at with We XX-patient Squibb’s of and collaboration, tissue evaluate topline can and our to XXXX. Nerlynx; in by response. our design goal we're and data is foundation presented NSABP Phase be Puma the in our our companies announce our EGFR drug principal We're HERX Genentech, the study X and critical Celcuity’s XXXX cancer at of Miami these is colorectal patients' being enrolled instead antibody, is Bristol-Myers have trial trial. trial Biotechnology Puma data type. last enrolled cell between evaluate Celcuity from report inhibitor, investigators pleased current completed interest. to to end metastatic patient of patient expected study was targeted trial study to in used not and is seeking response most collaborations they This status NSABP but clinical and solely correlate type completed to Genentech’s used being the we're with Unlike rationale. this its assess correlation from Conference, the the CELx pharmaceutical Cancer Breast to evaluated. Breast test
good. During move and last in timing on been and the of also track space the space, quarter, our ready XXXX and so current and design We're the in we foot in mid-May. now of every is office getting to we're We've utilized our new this finalized move we've square the space space. laboratory is the necessary
for will our the we Function To our the the a another progress track to financial our made during trial goals. results. collaboration quarter. to with to data on who development turn but interim we're we're pharmaceutical excited XXXX, review overall, I'll are tests year, obtain those So, complete and briefly meet summarize, X far, next our goals clinical now Signaling from the company to CELx very FACT to about three Vicky clinical initiate during of so
